Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Pharmaceuticals, PerkinElmer, Waters, Komen Foundation, Advion, Bruker, Cengent Therapeutics

Premium

Millennium to Lay off 600 by the end of 2004

Millennium Pharmaceuticals of Cambridge, Mass., said last week that it will reduce its headcount by about 600 to approximately 1,700 by the end of 2004 and concentrate its research and development operations into a single location in Cambridge, Mass. It will discontinue its operations in South San Francisco and Cambridge, UK.

The layoffs, which will start this month, will primarily occur in research, mostly in connection with early-stage discovery collaborations, as well as in general and administrative functions.

These measures result from Millennium’s new focus on developing and commercializing products in order to become profitable by 2006.

 

PerkinElmer in OEM with Nonlinear Dynamics

PerkinElmer of Boston and Nonlinear Dynamics of Newcastle upon Tyne, UK, said this week that they have signed a new OEM agreement.

Under the new contract, Nonlinear will develop a 2D gel analysis product, called ProFinder 2D, exclusively for PerkinElmer. ProFinder 2D will be available later this month, according to the companies.

 

Waters to Sell Ionalytics’ Ion Filter Instrument

Waters of Milford, Mass., and Ionalytics of Ottawa, Ontario, said this week that they had signed an agreement that allows Waters to market, sell, and support Ionalytics’ Selectra ion filter instrument as a front-end to Waters’ mass spectrometers. Selectra filters ions based on high field asymmetric waveform ion mobility spectro- metry (FAIMS), removing chemical noise before the ions enter the analyzer of the mass spectrometer.

 

Komen Grants Include Proteomics

Proteomics-related breast cancer research projects are among 131 grants totaling $21 million awarded by the Susan G. Komen Breast Cancer Foundation for fiscal year 2003 this week.

The proteomics research grants include: $249,956 to Jinong Li at Johns Hopkins for a project, “Capture breast cancer early: Detecting ductal carcinoma in situ by serum proteomic analysis using ProteinChip arrays and SELDI-mass spectrometry,” and $250,000 to Peter Oefner at the Stanford Genome Technology Center, for “Prospective study of the predictive power of surface-enhanced laser desorption ionization mass spectrometry in detecting early stage breast cancer.”

 

Advion and Waters to Co-market Mass Spec Products; Advion, ABI in Co-Marketing Talks

Advion BioSciences of Ithaca, NY, and Waters of Milford, Mass., said this week that they will jointly promote each other’s mass spectrometry products.

The agreement involves marketing and co-promotion of electrospray products and ensuring compatibility of Advion’s chip-based automated nanoelectrospray system NanoMate 100 with Waters’ mass spectrometers.

The two companies will also collaborate to develop and integrate Advion’s ChipSoft software with Waters’ MassLynx software.

Separately, company representatives from Applied Biosystems and Advion told ProteoMonitor this week that they are in talks about a similar co-marketing agreement, involving Advion’s NanoMate and ABI’s Q Star and 4000 Q Trap mass spectrometers.

 

Bruker, PNNL to Further Develop FTMS

Bruker Daltonics of Billerica, Mass., said this week that it had signed a follow-on Cooperative Research and Development Agreement with Batelle Memorial Institute, the operating and management contractor for the Department of Energy’s Pacific Northwest National Laboratory.

Under the agreement, Bruker will provide PNNL with its new Apex-Q hybrid FTMS. The research will focus on a technique developed by Richard Smith at PNNL, called Dynamic Range Enhancement for Advanced Mass Spectrometry or DREAMS, aiming at development and commercializaton for high-throughput proteomics by Fourier transform mass spectrometry.

This is the second CRADA between Bruker and Battelle/PNNL. In 2000, the two groups signed a CRADA to co-develop a hybrid Q-q-FTMS system, which resulted in the recently introduced Apex-Q FTMS.

 

Cengent Solves Co-Crystal Structure of Phosphatase

Cengent Therapeutics of San Diego (the merged product of SBI and Geneformatics) said this week it has determined the co-crystal structure of protein tyrosine phosphatase-1B with a novel small molecule inhibitor.

This inhibitor was developed using the company’s Genes-To-Leads lead prediction technology. It was found to be selective and reversible, highly potent in functional cell assays, and to lower glucose levels in diabetic mice. The company hopes that the co-crystal structure will help it design even more selective inhibitors.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.